BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Wednesday, 13 November 1996.
In its analysis, U.S. MARKET FOR SYNTHETICALLY DERIVED THERAPEUTIC PEPTIDES, the marketing consulting firm asserts that companies pioneering developments in the relatively young peptide industry will reap financial rewards for easing the suffering of millions of Americans suffering from prostate cancer, endometriosis, acromegaly, cardiovascular disease, cancer, HIV/AIDS, hepatitis, multiple sclerosis and osteoporosis.
Therapeutic peptides are available to patients suffering from various medical conditions. Chronic illnesses that are considered hormone dependent are a primary target of companies marketing peptide drugs.
Patients suffering from prostate cancer and endometriosis have been helped the most by therapeutic peptides.
Peptide products are expected to double by 1999, when as many as 11 new products are to appear on the market.
"In the United States, the potential increase in revenues for the therapeutic peptide market is tremendous," said Janice Gottschall, a medical analyst for Frost & Sullivan.
There are currently four peptide products expected to receive regulatory approval in the cardiovascular market, and the immunology market may have the most hopeful peptide to date.
A significant trend developing in the peptide industry is the emergence of an orally ingested medication. It is important to offer a patient a convenient medicine, and oral drugs have the highest patient-compliance ratio compared to injected and inhaled drugs. Another trend is toward longer-lasting doses.
Because the markets for well-known diseases are very competitive, peptide manufacturers are now finding that they must use aggressive marketing and educational programs in order to find commercial success.
This research by Frost & Sullivan details in length why some medical research and manufacturing companies stand to gain -- and some to lose -- peptide therapy market shares. Its analysis provides significant strategic insight into the direction and velocity of this market; companies receive recommendations for strategic action when purchasing this report, as well as a reliable source of continuing research by an international consulting firm dedicated to defining market problems, needs and opportunities.
Companies included in this study are: Abbott Laboratories, ALTEON, Inc., Amylin Pharmaceuticals, Inc., Anergen, Inc., Applied Microbiology, Inc., Aptein, Inc., Armour Pharmaceuticals, Asta Medica AG, Astra Pharmaceuticals, Ltd., AutoImmune, Inc., BASF Pharmaceuticals, Biogen, Inc., Biomeasure, Inc., Bio-Technology General Corp., Burzynski Research Institute, Inc.
Centocor, Inc., Ciba Pharmaceuticals (Novartis), City of Hope National Medical Center, Columbia Laboratories, Inc., Cortech, Inc., Cortex Pharmaceuticals, Inc., COR Therapeutics, Inc., Corvas International, Debiopharm, SA, Diatide, Inc., Duke University, Eli Lilly & Company, Endocon, Inc., Ferring Laboratories, Inc., Hoechst Marion Roussel Pharmaceuticals, Inc., Immunobiology Research Institute, Immunotherapeutics, Inc., Ingenex, Inc.
LEK Pharmaceutical Co., Magainin Pharmaceuticals, Inc., Merck & Co., Inc., Milkhaus, National Cancer Institute, National Institutes of Health, Neurex Corp., Neurobiological Technologies, Inc., Neurocrine Biosciences, Inc., Osteopharm, Ltd., Ortho Biotech, Inc., Parke-Davis, Pennsylvania State University, Peptech A/S, Peptide Technology, Pfizer, Inc., Pharmaceutical Discovery Corp., Pharmacia & Upjohn, Inc., Pierre Fabre, Inc., Proteus International, plc.
Research Corporation Technology, Rhone-Poulenc Rorer Pharmaceuticals, Roberts Pharmaceuticals Corp., Roche Bioscience, Sandoz Pharmaceutical Corp. (Novartis), Schering-Plough Laboratories, SciClone Pharmaceuticals, Inc., Scios, Inc., Scripps Clinic & Research Foundation, Searle & Co., Serono Laboratories, Inc., SmithKline Beecham Pharmaceuticals, Stanford University.
TAP Pharmaceuticals, Inc., Telios Pharmaceuticals, Inc., Temple University, Teva Pharmaceuticals, Inc., Texas Biotechnology, Thomas Jefferson University Hospital, Trimeris, Inc., Tulane University, Unigene Laboratories, Inc., United Biomedical, Inc., University of Nebraska, University of Tennessee, University of Texas Health Center, Wyeth-Ayerst Laboratories, Xoma Corporation, and Zeneca, Inc.
Frost & Sullivan is an international marketing consulting company that monitors the medical industry for market trends, market measurements, and strategies. This ongoing research is utilized to update a series of research publications and to support industry participants with customized consulting needs. Free executive summaries of all Frost & Sullivan reports are available to the press.
Report: 5030-52 Publication Date: May 1996 Price: $2,695
CONTACT: Frost & Sullivan Russ Pecoraro, 415/961-9000 ext. 488 (California) rpecoraro@frost.com http://www.frost.com or Kristina Menzefricke, 44/171-730-3438 (London) Stefan Gerhardt, 49/69-235057 (Frankfurt)
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961113
BW961115
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .